https://www.selleckchem.com/pr....oducts/JNJ-7706621.h
raft model. Our work represents a potential strategy for enhancing PDA tumor penetration and immunochemotherapy. Talimogene laherparepvec (T-VEC) is an oncolytic virus based on herpes simplex virus type 1 approved for intralesional treatment of advanced melanoma. In this article, we review the clinical literature on T-VEC for advanced melanoma and provide a practical approach to using T-VEC in the dermatologic surgery and oncology clinic. PubMed was used to conduct a systematic literature review of articles describing the structure,
Curtir
Comentario
Compartilhar
